Add this result to my export selection Medical Device Alerts issued in June 2019 Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 17 July 2019 An alert was issued about Dialog+ haemodialysis machines. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 23 September 2020 Following a review of the risks associated with use of opioid medicines for non-cancer pain, the Commission on Human Medicines (CHM) has recommended that fentanyl transdermal patches are... Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Letters and drug alerts sent to healthcare professionals in July 2020 Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 26 August 2020 A summary of letters and drug alerts recently sent to healthcare professionals, including recommendations to reduce handling errors with leuprorelin-containing depot medicines. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Letters and drug alerts sent to healthcare professionals in June 2020 Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 31 July 2020 A summary of letters and drug alerts recently sent to healthcare professionals. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Emollients and risk of severe and fatal burns: new resources available Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 26 August 2020 We inform healthcare professionals of the recent campaign to promote awareness of the risk and new resources available to support safe use following previous advice to health and care professionals. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Letters and drug alerts sent to healthcare professionals in April 2020 Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 21 May 2020 A summary of letters and drug alerts recently sent to healthcare professionals. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Coronavirus (COVID-19): latest guidance for medicines safety Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 27 April 2020 Key MHRA advice and guidance issued so far on medicines safety and pharmacovigilance, including on reporting to the Yellow Card Scheme. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Letters and drug alerts sent to healthcare professionals in March 2020 Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 27 April 2020 A summary of letters and drug alerts recently sent to healthcare professionals. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 21 May 2020 Guidance has been published to support initiation of valproate in female patients and for annual review and pregnancy testing during the coronavirus pandemic. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 21 May 2020 Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19. Read Summary Type: Safety Alerts (Remove filter)